Douglas A Jabs1, Mark L Van Natta2, Efe Sezgin2, Jeong Won Pak3, Ronald Danis3. 1. Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: douglas.jabs@mssm.edu. 2. Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of Ophthalmology, University of Wisconsin, Madison, Madison, Wisconsin.
Abstract
PURPOSE: To evaluate the prevalence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). DESIGN: Cross-sectional study of patients with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS. METHODS: Intermediate-stage AMD was determined from enrollment retinal photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study grading system. Graders were masked as to clinical data. RESULTS: Of 1825 participants with AIDS and no ocular opportunistic infections, 9.9% had intermediate-stage AMD. Risk factors included age, with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 1.6, 2.3, P < .001) for every decade of age; the prevalence of AMD ranged from 4.0% for participants 30-39 years old to 24.3% for participants ≥60 years old. Other risk factors included the human immunodeficiency virus (HIV) risk groups of injection drug use (OR = 2.4, 95% CI 1.5, 3.9, P < .001) or heterosexual contact (OR = 1.9, 95% CI 1.3, 2.8, P = .001). Compared with the HIV-uninfected population in the Beaver Dam Offspring Study, there was an approximate 4-fold increased age-adjusted prevalence of intermediate-stage AMD. CONCLUSIONS: Patients with AIDS have an increased age-adjusted prevalence of intermediate-stage AMD compared with that found in a non-HIV-infected cohort evaluated with similar methods. This increased prevalence is consistent with the increased prevalence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infected persons when compared to non-HIV-infected persons. Published by Elsevier Inc.
PURPOSE: To evaluate the prevalence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired immunodeficiency syndrome (AIDS). DESIGN: Cross-sectional study of patients with AIDS enrolled in the Longitudinal Study of the Ocular Complications of AIDS. METHODS: Intermediate-stage AMD was determined from enrollment retinal photographs by graders at a centralized Reading Center, using the Age-Related Eye Disease Study grading system. Graders were masked as to clinical data. RESULTS: Of 1825 participants with AIDS and no ocular opportunistic infections, 9.9% had intermediate-stage AMD. Risk factors included age, with an odds ratio (OR) of 1.9 (95% confidence interval [CI] 1.6, 2.3, P < .001) for every decade of age; the prevalence of AMD ranged from 4.0% for participants 30-39 years old to 24.3% for participants ≥60 years old. Other risk factors included the human immunodeficiency virus (HIV) risk groups of injection drug use (OR = 2.4, 95% CI 1.5, 3.9, P < .001) or heterosexual contact (OR = 1.9, 95% CI 1.3, 2.8, P = .001). Compared with the HIV-uninfected population in the Beaver Dam Offspring Study, there was an approximate 4-fold increased age-adjusted prevalence of intermediate-stage AMD. CONCLUSIONS:Patients with AIDS have an increased age-adjusted prevalence of intermediate-stage AMD compared with that found in a non-HIV-infected cohort evaluated with similar methods. This increased prevalence is consistent with the increased prevalence of other age-related diseases in antiretroviral-treated, immune-restored, HIV-infectedpersons when compared to non-HIV-infectedpersons. Published by Elsevier Inc.
Authors: Douglas A Jabs; Mark L Van Natta; Janet T Holbrook; John H Kempen; Curtis L Meinert; Matthew D Davis Journal: Ophthalmology Date: 2007-01-25 Impact factor: 12.079
Authors: C D Holtzer; M A Jacobson; W K Hadley; L Huang; H D Stanley; R Montanti; M K Wong; J D Stansell Journal: AIDS Date: 1998-10-01 Impact factor: 4.177
Authors: Yara T E Lechanteur; Johannes P H van de Ven; Dzenita Smailhodzic; Camiel J F Boon; B Jeroen Klevering; Sascha Fauser; Joannes M M Groenewoud; Gert-Jan van der Wilt; Anneke I den Hollander; Carel B Hoyng Journal: Invest Ophthalmol Vis Sci Date: 2012-08-24 Impact factor: 4.799
Authors: Douglas A Jabs; Mark L Van Natta; Michael F Schneider; Jeong Won Pak; Garrett Trang; Norman G Jones; Jeffrey Milush; Peter W Hunt Journal: AIDS Date: 2022-02-01 Impact factor: 4.632
Authors: E Schaftenaar; N S Khosa; G S Baarsma; C Meenken; J A McINTYRE; A D M E Osterhaus; G M G M Verjans; R P H Peters Journal: Epidemiol Infect Date: 2017-05-19 Impact factor: 4.434
Authors: Douglas A Jabs; Mark L Van Natta; Jeong Won Pak; Ronald P Danis; Peter W Hunt Journal: Invest Ophthalmol Vis Sci Date: 2018-02-01 Impact factor: 4.799
Authors: Douglas A Jabs; Mark L Van Natta; Garrett Trang; Norman Jones; Jeffrey M Milush; Ryan Cheu; Nichole R Klatt; Jeong Won Pak; Ronald P Danis; Peter W Hunt Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799